



3rd

Two Coasts of the Aegean

ILD & PH


October 29–November 1, 2026

Grand Hyatt İzmir
İstinyePark Hotel

TURKISH **GREEK**
WORKSHOP
İZMİR



A Collaboration Between the Schools
of Medicine, Ege University and the
University of Crete



ΠΕΡΙΦΕΡΕΙΑ
ΚΡΗΤΗΣ
REGION OF CRETE

POSTGRADUATE COURSES & SCIENTIFIC PROGRAM



ILD POSTGRADUATE COURSE

29 October 2026 - PRE-CONGRESS DAY

HALL A - Practical ILD Masterclass

08:20-10:10	ILD Course Session I – Practical diagnosis and early decision-making Chairs: Katerina Antoniou, Selen Bayraktaroğlu, Nikolaos Tzanakis	
08:20-08:30	Welcome and course objectives	Nesrin Moğulkoç Bishop, Katerina Antoniou
08:30-08:55	How to approach a new ILD patient in 2026	Theodoros Karampitsakos
08:55-09:20	HRCT pattern recognition in fibrotic ILD: a practical approach	Helmut Prosch
09:20-09:45	Physiology of advanced lung disease: what PFTs and exercise reveal	Theodoros Vassilakopoulos
09:45-10:10	IPF, PPF and non-IPF fibrosis: practical distinctions	Pilar Rivera-Ortega
10:10-10:40	Coffee Break	
10:40-12:00	ILD Course Session II – Phenotypes, tissue, management and referral Chairs: Kemal Can Tertemiz, Murat İnanç, Katerina Antoniou	
10:40-11:00	When to consider genetic testing at the diagnosis of fibrotic ILDs?	Effrosyni D. Manali
11:00-11:20	CTD-ILD for pulmonologists: red flags and referral triggers	George Margaritopoulos
11:20-11:40	Cryobiopsy, pathology and MDD: where tissue still matters	Claudia Ravaglia
11:40-12:00	Advanced ILD and transplant referral: timing, risk and the window of opportunity	Bedrettin Yildizeli
12:00-13:30	Lunch	
13:30-14:45	Speed MDD: Five images, five diagnoses, five decisions Chair: Funda Coşkun Expert board: Recep Savaş, Çetin Atasoy, Mustafa Erdoğan, Ayşe Füsün Topçu, Gülfer Okumuş, Gülrü Polat	
13:30-13:45	Case 1 - Department of Pulmonology, Ege University	Nur Toreyin
13:45-14:00	Case 2 - Department of Radiology, Ege University	Selen Bayraktaroğlu
14:00-14:15	Case 3 - Department of Pulmonology, Istanbul University	Züleyha Bingöl
14:15-14:30	Case 4 - Department of Pulmonology, Ankara University	Özlem Özdemir Kumbasar
14:30-14:45	Case 5 - Department of Pulmonology, Dokuz Eylül University	Erencan Beğiç
14:45-15:15	Coffee Break	
15:15-17:00	Young ILD Case Forum: “What would you do next?” Chair: Eyüp Sabri Uçan Discussants: Şule Taş Gülen, Pınar Çelik, Züleyha Bingöl, Muzaffer Onur Turan, Enver Yalnız	
15:15-15:30	Case 1 - Department of Pulmonology, HOCH Health Ostschweiz, Cantonal Hospital St. Gallen	Ekrem Temizel
15:30-15:45	Case 2 - Department of Pulmonology, Ege University	Burak Gökçe
15:45-16:00	Case 3 - Clinic of Pulmonology, University Health Sciences İzmir Dr. Suat Seren Chest Diseases and Chest Surgery Training and Research Hospital	Ömer Selim Unat
16:00-16:15	Case 4 - Clinic of Pulmonology, University Health Sciences İzmir City Hospital	Yelda Varol
16:15-17:00	Case 5 - Clinic of Pulmonology, Denizli Tavas State Hospital	Nazlı Çetin



PH POSTGRADUATE COURSE

29 October 2026 - PRE-CONGRESS DAY

HALL B - PAH and PH Masterclass

08:20–10:10	PH Course Session I – First evaluation, haemodynamics and risk Chairs: Meral Kayıkçıoğlu, Bahri Akdeniz, Ioanna Mitrouska	
08:20–08:30	Welcome and course objectives	Nesrin Moğulkoç Bishop, Meral Kayıkçıoğlu
08:30–08:55	PH classification in 2026: distinguishing groups 1 to 4 at first evaluation	Ioanna Mitrouska
08:55–09:20	Advanced RHC workshop: borderline haemodynamics, difficult tracings and clinical decisions	Burçak Kılıçkiran Avcı
09:20–09:45	Echocardiography in PH: from suspicion to follow-up	Gerry Coghlan
09:45–10:10	Practical risk stratification in PAH: applying low-risk goals in daily care	Ardeschir Ghofrani
10:10–10:40	Coffee Break	
10:40–12:00	PH Course Session II – Treatment, RV function and difficult haemodynamics Chairs: Burçak Kılıçkiran Avcı, Ersan Atahan	
10:40–11:00	PAH treatment algorithms: a practical stepwise approach	Bahri Akdeniz
11:00–11:20	RV function in PAH: what cardiologists add to the PH team	Meral Kayıkçıoğlu
11:20–11:40	RHC fundamentals in PH: numbers, waveforms and common interpretation traps	Gerry Coghlan
11:40–12:00	Interactive case synthesis: applying risk, RV function and RHC data to PAH treatment decisions	Faculty-led discussion: Robin Condliffe, Meral Kayıkçıoğlu, Gülfer Okumuş
12:00–13:30	Lunch	
13:30–15:00	PH Case Board: Four patients, four pathways Chair: İbrahim Başarıcı Expert board: Meral Kayıkçıoğlu, Bahri Akdeniz, İsmail Hanta, Ersan Atahan, Sanem Nalbantgil	
13:30–13:45	Case 1 - Department of Pulmonology, Istanbul University-Cerrahpaşa	Şermin Börekçi
13:45–14:00	Case 2 - Department of Cardiology, Ege University	Emre Demir
14:00–14:15	Case 3 - Department of Cardiology, Ege University	Bekir Serhat Yıldız
14:15–14:30	Case 4 - Department of Cardiology, Akdeniz University	İbrahim Başarıcı
14:30–15:00	Discussion	Expert board
15:00–15:15	Coffee Break	
15:15–16:15	PH Case Board: BPA & PEA Chair: Bahri Akdeniz Expert board: Burçak Kılıçkiran Avcı, Sanem Nalbantgil, Tahir Yağdı, Sevda Şener Cömert, Selen Bayraktaroğlu	
15:15–15:45	Case-based discussion: BPA experiences	Halil Ataş
15:45–16:15	Case-based discussion: Pulmonary endarterectomy experiences	Bedrettin Yıldızeli



ILD AND GROUP 1 PAH AS DISTINCT DISEASES

30 October 2026

MAIN SCIENTIFIC PROGRAMME DAY 1

08:30–09:00	Opening Ceremony The Aegean Bridge: From Collaboration to a Shared Scientific Network Opening remarks: Tahir Yağdı, Deputy Rector of Ege University (In the event of their presence) Arzu Yorgancıoğlu, Representative of ERS Marc Humbert, Representative of ERN Theodoros Vassilakopoulos, Representative of Greek Government Nesrin Mogulkoc Bishop, Representative of Ege University School of Medicine Katerina Antoniou, Representative of University of Crete School of Medicine	
09:00–10:20	SESSION I Fibrotic ILD in 2026: Phenotypes, Progression and Treatment Timing Chairs: Nesrin Moğulkoç Bishop, Katerina Antoniou, Claudia Ravaglia	
09:00–09:20	Fibrotic ILD in 2026: from slowing decline to changing disease trajectory	Luca Richeldi
09:20–09:40	Early fibrotic ILD and ILA: when does risk become disease?	Maria Molina-Molina
09:40–10:00	Progressive pulmonary fibrosis: one syndrome or many diseases?	Wim Wuyts
10:00–10:20	Clinical–radiological progression: what should trigger treatment change?	Argyris Tzouvelekis
10:20–10:50	Coffee Break	
10:50–12:10	SESSION II Under-recognised and High-impact ILD Phenotypes Chairs: George Margaritopoulos, Nazia Chaudhuri, Helmut Prosch	
10:50–11:05	Hypersensitivity pneumonitis in 2026: from antigen identification to long-term management	Şehnaz Yıldızeli
11:05–11:20	IPF and lung cancer: how screening CT is changing the early detection of ILD and ILD–lung cancer overlap	Helmut Prosch
11:20–11:35	Drug-induced ILD in the era of immune checkpoint inhibitors	George Margaritopoulos
11:35–11:50	Cancer therapy-induced interstitial lung disease (DI-ILD): an international multicentre registry	Nesrin Öcal
11:50–12:10	Panel discussion: is modern medicine creating a new ILD population?	Panelists: Çetin Atasoy, Pınar Gürsoy, Nazia Chaudhuri, Helmut Prosch
12:10–13:00	Lunch Satellite Symposium I - NOBEL İLAÇ Genetics and Precision Medicine in Pulmonary Fibrosis Chair: Nurdan Köktürk	
12:10–12:35	Journey in discovering and studying MUC5B in pulmonary fibrosis	David Schwartz
12:35–13:00	Familial Pulmonary Fibrosis: When to Suspect, When to Test and How to Counsel Families	Effrosyni D. Manali



ILD AND GROUP 1 PAH AS DISTINCT DISEASES

30 October 2026

MAIN SCIENTIFIC PROGRAMME DAY 1

13:00–14:20	SESSION III Group 1 PAH: Modern Phenotyping and Disease-modifying Treatment Chairs: Nesrin Öcal, Gülfer Okumuş	
13:00–13:25	Group 1 PAH in 2026: from risk stratification to disease modification	Marc Humbert
13:25–13:45	Haemodynamic and clinical phenotyping in PAH: beyond classification	Gabor Kovacs
13:45–14:05	Next-generation PAH treatment: from risk-based escalation to precision therapy	Ardeschir Ghofrani
14:05–14:20	Right ventricular–pulmonary arterial coupling as a treatment target in PAH	Robin Condliffe
14:20–14:50	Coffee Break & Group Photograph	
14:50–15:50	PRO–CON DEBATE Antifibrotic Therapy in Fibrotic ILD: Treat Early or Wait for Progression? Chairs: Katerina Antoniou, Nesrin Moğulkoç Bishop, Funda Coşkun	
14:50–15:05	Pro: Anticipate Progression: Antifibrotic Therapy Before Documented PPF	Pilar Rivera-Ortega
15:05–15:20	Con: Demonstrate Progression: Antifibrotic Therapy Once PPF Is Documented	Nazia Chaudhuri
15:20–15:30	PRO Rebuttal	
15:30–15:40	PRO Rebuttal	
15:40–15:50	Discussion & Audience Vote	Discussants: Luca Richeldi, Wim Wuyts
15:50–16:20	Coffee Break	
16:20–18:00	PAH Clinical Courtroom – Upfront Intensive Therapy or Personalised Escalation? Chair: Robin Condliffe Expert board: Marc Humbert, Ardeschir Ghofrani, Özlem Erçen Diken, Derya Kocakaya	
16:20–16:35	Case 1: Young idiopathic PAH with high-risk features	Bedrettin Yıldızeli
16:35–16:50	Case 2: Older PAH patient with comorbidities: true PAH or mixed phenotype?	Derya Kocakaya
16:50–17:05	Case 3: CTD-ILD Associated PH: vascular disease, lung disease or both?	Murat İnanç
17:05–17:20	Case 4: Worsening PH - or something else? The diagnostic trap	Ender Terzioğlu
17:20–17:30	Courtroom verdict: what should change in treatment strategy?	Robin Condliffe
17:30–18:00	Respiratory system as the main determinant of dyspnea in patients with pulmonary hypertension	Vagia Stamatopoulou



PH-ILD, CTD-ILD/PAH, IMAGING AND TRIALS

31 October 2026

MAIN SCIENTIFIC PROGRAMME DAY 2

08:30–09:00	Morning Keynote: When fibrosis meets the pulmonary circulation: The PH-ILD challenge Chairs: Nesrin Mogulkoc Bishop, Ioanna Mitrouska	Katerina Antoniou
09:00–10:40	SESSION IV PH-ILD and the Grey Zone: PAH, Group 3 PH or Both? Chairs: Özlem Özdemir Kumbasar, Ali Akdoğan	
09:10–09:20	PH-ILD in 2026: definitions, phenotypes and clinical consequences	Katerina Antoniou
09:20–09:40	Severe PH with mild ILD: PAH with lung involvement or PH-ILD?	Marc Humbert
09:40–10:00	The ILD clinician's view: when PH changes prognosis and treatment strategy	Theodoros Karampitsakos
10:00–10:20	Turkish PH-ILD experience: lessons from difficult clinical cases	Nesrin Mogulkoc Bishop
10:20–10:40	Panel question: "When should we catheterise the ILD patient?"	İbrahim Başarıcı
10:40–11:10	Coffee Break	
11:10–12:10	SESSION V Imaging and AI at the Fibrosis–Vascular Interface Chairs: George Margaritopoulos, Meltem Tor, Pilar Rivera-Ortega	
11:10–11:40	AI-derived CT vascular, airway and textural metrics as trial endpoints in pulmonary fibrosis	Luca Richeldi
11:40–12:10	Hot discussion: "AI says progression, clinician says stability – who wins?"	Oliver Distler
12:10–13:10	Lunch Satellite Symposium II Targeted Therapies Across the Fibrosis–Vascular Spectrum Chair: Nesrin Moğulkoç Bishop, Gerry Coghlan	Marc Humbert (30 min)



PH-ILD, CTD-ILD/PAH, IMAGING AND TRIALS

31 October 2026

MAIN SCIENTIFIC PROGRAMME DAY 2

13:10–14:30	SESSION VI Autoimmune Disease at the Crossroads: CTD-ILD, CTD-PAH and CTD-PH-ILD Chairs: Murat İnanç, Katerina Antoniou, Sevda Şener Cömert	
13:10–13:30	Systemic sclerosis-associated ILD: what has changed in treatment strategy?	Oliver Distler
13:30–13:50	Systemic sclerosis-associated PAH: a model disease for Group 1 PAH	Ali Akdogan
13:50–14:10	CTD-ILD with PH: one patient, two pathways, one decision	Pilar Rivera-Ortega
14:10–14:30	Should every CTD-ILD patient be screened for PH?	Gerry Coghlan
14:30–15:50	GREAT DEBATE PH-ILD Treatment: Are We Treating the Lung, the Vessel or the Wrong Patient? Chairs: Luca Richeldi, Marc Humbert, Nesrin Moğulkoç Bishop	
14:30–14:50	Keynote Lecture: Never give up on a pathway: Mosliciguat rewrites the sGC story in PH-ILD	Marc Humbert
14:50–15:10	Position 1: The main target is the fibrotic lung	Luca Richeldi
15:10–15:30	Position 2: The main target is the pulmonary vasculature in selected patients	Ardeschir Ghofrani
15:30–15:50	Position 3: The main target is phenotyping before treating	George Margaritopoulos
15:50–16:15	Coffee Break	
16:15–17:15	SESSION VII Genetic and Molecular Frontiers in Progressive Pulmonary Fibrosis Chairs: Effrosyni D. Manali, David Schwartz, Argyrios Tzouvelekis	
16:15–16:45	The paradigm of Hermansky Pudlak syndrome in Greece, Cyprus and Türkiye	Effrosyni D. Manali
16:45–17:15	Multi-Omics Uncovers Shared Biomarkers and Immune Mechanisms of Progressive Pulmonary Fibrosis: Toward Precision Medicine Across the ILD Spectrum	Resat Cinar
17:15–17:30	Coffee Break	
17:30–18:45	TRIALISTS' ARENA Designing the Next Generation of ILD, PAH and PH-ILD Trials Chairs: Argyrios Tzouvelekis, Katerina Antoniou Discussants: Nesrin Moğulkoç Bishop, Marc Humbert, Theodoros Karampitsakos	
17:30–17:45	Trial enrichment in fibrotic ILD: selecting the right patient before progression	David Schwartz
17:45–18:00	PAH trials beyond 6MWD: risk, RV function and clinical worsening	Marc Humbert
18:00–18:15	PH-ILD trials: which patient, which endpoint, which therapy?	Ardeschir Ghofrani
18:15–18:30	Translational targets: from vascular remodelling to fibrosis modification	Resat Cinar
18:30–18:45	One impossible question: "If we designed the perfect ILD–PH trial today, what would the primary endpoint be?"	Luca Richeldi



COLLABORATIVE CLINICAL RESEARCH


01 November 2026

HALF-DAY SCIENTIFIC PROGRAMME

08:30–09:00	Poster Session Chairs: Fulsen Bozkuş, Pınar Yıldız, Ersan Atahan	
09:00–09:30	Recent advances in Interventional Pneumology in ILDs Chairs: Göksel Altınışık, Kemal Can Tertemiz, Nikolaos Tzanakis	
09:00–09:15	Beyond diagnosis: Emerging interventional approaches in ILD	Semra Bilaçeroğlu
09:15–09:30	Whole lung lavage in the era of targeted therapy: Still the cornerstone?	Efsun Gonca Uğur Chousein
09:30–10:30	TURKISH–GREEK COLLABORATIVE PROPOSAL FOR INTERVENTIONAL PNEUMONOLOGY Chairs: Göksel Altınışık, Ersan Atahan	
09:30–10:30	Oscillometry in ILDs and sarcoidosis: what's new-new proposal: Non invasive assessment of rheumatoid lung	Karagiannis Konstantinos, Konstantina Symvoulaki
10:30–10:45	Coffee Break	
10:45–12:00	TURKISH–GREEK COLLABORATIVE RESEARCH FORUM Completed, Ongoing and Proposed Studies Chairs: Effrosyni D. Manali, Nesrin Mogulkoc Bishop, George Margaritopoulos, Emmanouil Symvoulakis	
10:45–11:00	What Have We Already Built Together? Lessons from Previous Turkish–Greek ILD Collaborations	Effrosyni D. Manali
11:00–11:15	The protective impact of vaccination on survival and risk of AE-IPF (Turkish cohort vs Greek cohort)	Nesrin Moğulkoç Bishop, Ioannis Tomos
11:15–11:30	Toward an Aegean PH-ILD Registry	Nesrin Mogulkoc Bishop
11:30–11:45	Investigator Publication Pipeline for 2027	Nur Toreyin
11:45–12:00	ATLAS - Sarcoidosis	Ekrem Temizel
12:00–12:30	Closing and Award Ceremony	Nesrin Mogulkoc Bishop, Katerina Antoniou



A Collaboration Between the Schools
of Medicine, Ege University and the
University of Crete



3rd

Two Coasts of the Aegean

ILD & PH

October 29-November 1, 2026

Grand Hyatt İzmir
İstinyePark Hotel

TURKISH **GREEK**
WORKSHOP
İZMİR

Organisation Committee

Nesrin Moğulkoç Bishop

Professor of Respiratory Medicine with Expertise in
Interstitial Lung Disease and Pulmonary Hypertension
Ege University School of Medicine Department of
Respiratory Medicine Bornova, İzmir, Türkiye

Katerina Antoniou

Professor of Respiratory Medicine and
Head of Lab. of Cellular and Molecular
Pulmonology, University of Crete,
Greece



Organization Secretariat

19 Mayıs Mah. Halaskargazi Cad. T. Cemal Sk.
Cumhuriyet Apt. No:7 D:1, 34360 Şişli / İstanbul-Türkiye
Phone: +90 212 230 78 68 - Fax: +90 212 234 78 68

E-mail: ild-ph@invictuscongress.org - www.invictuscongress.org